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Introduction 
 Optimal treatment for ST-elevation myocardial infarction (STEMI) is based on a reperfusion strategy 
employing either primary percutaneous coronary intervention (PPCI) or thrombolytic therapy (TT). A 
sizable proportion of STEMI patients are not reperfused, time delays are frequently unacceptable1 and very 
few patients receive all the guideline-recommended therapies in a timely manner.  Decision-making in the 
pre-hospital setting is pivotal for optimal STEMI care, and delays in therapy cannot later be compensated. 
Thus, the empowerment of paramedical staff is key to successful pre-hospital STEMI management. This 
requires the implementation of systems of care (STEMI networks), in which the  Emergency Medical 
Service (EMS), non-PCI-capable hospitals, and hospitals with PCI facilities cooperate closely in order to 
reduce the total ischaemic time, increase the number of patients receiving reperfusion therapy, and to reduce 
heart failure and mortality 2 .  
 
Delays 
The total ischaemic time (Figure 1) is often unacceptably long with only 11-15% patients  treated within the 
recommended time intervals. 3  
Patient delay.  An early first call to the EMS is desirable as rapid diagnosis and treatment at the scene has 
been shown to save lives and prevent complications.   The patient’s decision time (PDT) has historically 
remained constant at between 1-3 hours.  Patients with longer PDTs tend to be older, female and diabetic, 
with  atypical symptoms. There is significant variation in the use of EMS in STEMI (28-82% patients) and in 
the PDTs (81-174 mins) throughout Europe. While several public initiatives have been successful in 
shortening PDTs, such campaigns have only a temporary impact.    
An integral part of the EMS is triage by the emergency medical dispatcher. First medical contact is defined 
as the time at which STEMI diagnosis is made using ECG, irrespective of the setting. 
Pre-hospital organisation. Not all patients referred for PPCI receive optimal percutaneous reperfusion (i.e. 
PCI performed in a timely manner by an experienced team), and even in urban locations a minority still 
require pre-hospital thrombolysis (PH-T)4. Geographical considerations and distribution of PPCI centres are 
two factors that contribute to the variability in European rates (5-92%).5 The best evidence for reperfusion 
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strategies is based on in-hospital STEMI studies, and more high-quality research on the pre-hospital 
environment is needed.  The key to diagnosis is the pre-hospital electrocardiogram (PH-ECG)6, interpreted 
on site and/or transmitted for interpretation  
 
Pre-hospital ECG 
The use of the PH-ECG is widespread in some countries and has been shown to reduce the time to 
reperfusion and mortality in patients with STEMI.   Trained paramedics can identify STEMI with a good 
sensitivity and specificity, with multiple studies demonstrating that PH-ECGs decrease door-to-needle (D2N) 
and door-to-balloon (D2B) times.7  
 
Reperfusion strategies 
PH-T significantly reduces reperfusion time when compared with awaiting IH-T, increases the odds of 
aborted MI and improves outcome8.   The advantages of integrating  TT and PCI have been demonstrated in 
several studies, and in order to facilitate this, networks for STEMI management should be developed on a 
national and/or regional level, with continued measurement of outcome and quality metrics.  
 
Registries and STEMI networks: organization and outcome in practice 
STEMI mortality reported in registries is higher than in randomized clinical trials (RCTs). As the results of 
RCTs may only be applicable to 50% of patients in clinical practice, registry data may provide additional 
information, including the challenges in implementing RCT-derived recommendations. As shown from 
registry data, an increase in the PPCI-related delay (D2B minus D2N time) is associated with higher 
mortality rates. The time point at which PPCI loses its survival advantage over fibrinolysis varies 
considerably between subgroups, from <1 hour to 3 hours9. Registry data also show that field transfer is 
faster than inter-hospital transfer, resulting in more patients achieving a D2B time < 90mins. The main 
findings10-13 of selected European registries on pre-hospital STEMI care are shown in Table 1. 
 
Pre-hospital adjuvant therapies 
Several recommendations have been made to attempt to standardise care and reduce major adverse cardiac 
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events (MACE) and mortality in pre-hospital STEMI management (Table 2). Some drugs effective for  in-
hospital STEMI treatment are not indicated (GP IIb/IIIa inhibitors) or are lacking data in the pre-hospital 
setting (prasugrel, bivalirudin). 
 
Pre-hospital management of STEMI complications  
Timely and appropriate pre-hospital management can stabilise the patient, enabling safe transportation to the 
most appropriate hospital for more definite treatment.  
Cardiac arrest. The highest proportion of deaths due to MI occur early during the pre-hospital phase, before 
any medical support is at hand. The commonest cause is ventricular fibrillation, induced by ischaemia and 
reperfusion. In patients with no return of spontaneous circulation (ROSC), TT does not improve survival14.   
PPCI is an alternative for reperfusion in survivors of out-of-hospital cardiac arrest, and may be an 
independent predictor of survival.15    
Therapeutic hypothermia should be part of the standardised treatment strategy for comatose survivors of 
cardiac arrest.  
Cardiac arrhythmias.  Arrhythmias are associated with increased mortality in acute coronary syndromes 
(ACS).  Basic and advanced life-support algorithms and defibrillation/cardioversion should be applied where 
indicated.  Beta-blockers and amiodarone may be considered in case of ventricular tachyarrhythmias; 
alternative drugs are class 1A/1B antiarrhythmics. 
Acute bradycardia due to STEMI.  Complete heart block during STEMI is associated with  a high mortality 
rate. Severe bradycardia and high-grade atrio-ventricular block may be reversed by i.v. atropine sulfate in 
inferior or posterior acute myocardial infarction (AMI), while in anterior AMI emergency pacing may be 
required. 
Pulmonary oedema. Heart failure during STEMI is associated with poor short- and long-term prognosis, and 
PPCI is preferred in STEMI complicated by pulmonary oedema. Minor degrees of pulmonary oedema often 
respond to nitrates and diuretics, and in the absence of hypotension, i.v. nitroglycerine should be 
administered except in the presence of right ventricular infarction. Oxygen should be administered to 
patients with breathlessness and/or clinical signs of heart failure and/or cardiogenic shock (CS), and 
continuous positive airway pressure or endotracheal intubation with ventilatory support may be required.16  
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Morphine should be used only when clinically indicated.  
Cardiogenic shock. CS complicates AMI in 2.8-11% of cases, with a median time from AMI onset of 6.2 
hours, and a mortality rate > 50%.   PPCI is the preferred option in patients with CS and high-risk features,17 
with TT where PPCI is likely to be delayed.  Early diagnosis and treatment of established and developing CS 
is paramount. Here patients should be transported to PCI- and intra-aortic balloon pump-capable hospitals.  
Pre-hospital treatment of CS includes volume administration (in the absence of pulmonary oedema), oxygen 
(to achieve O2 saturation > 95%), and inotropic support (dobutamine and dopamine) if the systolic blood 
pressure is <90 mmHg.  In such cases, a low threshold for intubation and mechanical ventilation exists.    
Right ventricular infarction.This should be suspected where the clinical picture is of hypotension, clear lung 
fields and a raised jugular venous pressure in a patient with an inferior STEMI. ST-segment elevation in V4R 
is also suggestive. Right ventricular preload should be maintained and vasodilators avoided. Although 
limited fluid expansion is effective in many cases, additional inotropic support may be required.   PPCI is the 
preferred therapeutic option, with TT where PPCI is likely to be delayed.  
 
Education 
The educational challenges for improved pre-hospital care are considerable, ranging from EMS personnel to 
hospital-based cardiologists, nurses and other paramedical staff, funding bodies, policy makers and planners 
of health care. 
EMS systems vary in their approach to receiving and prioritising emergency calls, ranging from a physician 
to computerised priority dispatch algorithms.  EMS models can be dichotomised as the Franco-German 
model (physicians in the control room and in ambulances), or the Anglo-American mode 
(paramedics/emergency medical technician-staffed ambulances, working to agreed protocols, supported by 
physician direction and/or telemedicine). The duration of training and degree of autonomy varies widely 
between programmes.  
The knowledge, skills and behaviours outlined in the ACS section of the ESC Core Curriculum for the 
general cardiologist could be expected to apply, in various degrees, to all professionals engaged in pre-
hospital STEMI care.  Education of EMS staff in clinical research is of value, to facilitate  safe and ethical 
recruitment to approved, well-designed studies.  
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Training  
The need for a medical specialty. Emergency medicine (EM) is the medical specialty with the principal 
mission of evaluating, managing, treating and preventing unexpected illness and injury. It is a practice in 
which time is critical.   The second EuSEM Core Curriculum for emergency medicine stated a minimum of 5 
years in a recognised training program for EM specialists.18   
The need for a cardiological sub-specialty.  Patients admitted to the Intensive Cardiac Care Units (ICCUs) 
are increasingly older, have more severe cardiac conditions and associated comorbidities, with more than 
50% having important co-morbidities. To deliver optimal treatment to this patient population requires 
cardiologists to have full knowledge of the range of techniques and procedures required in intensive acute 
cardiac care (IACC).19 Cardiologists working in ICCUs must therefore adapt their knowledge and abilities to 
these new demands. The process of certification in IACC should standardise training in the specialty and 
facilitate delivery of state-of-the-art treatment to patients admitted to ICCUs in Europe.20   
 
Summary and conclusions 
The pre-hospital phase is the most critical in STEMI treatment.  Minimising patient-related delay is the first 
key step in STEMI treatment: public/patient education campaigns, community organisation, and the presence 
of an unique European-wide emergency telephone number may be  advisable.  The availability of automated 
external defibrillators (AEDs) in public places may be of value. The ambulance service has a pivotal role in 
STEMI management and cardiac arrest. All emergency ambulances should be equipped with defibrillators, 
12-lead electrocardiographs and staffed with at least one person proficient in advanced cardiac life support. 
ECG transmission/ teleconsultation may be useful.  
Implementation of systems of care has a pivotal role in modern STEMI treatment, based on networks among 
medical and cardiology institutions of different technological levels, connected by an effective EMS.  There 
are two main models of transfer; the hub-and-spoke transfer system and the STEMI receiving centre (SRC). 
In the first model, patients presenting to a non-PCI capable hospital are either treated with TT or 
immediately transferred for PPCI. In the second model, non-SRC are bypassed by transport systems, 
delivering patients directly to an experienced PPCI centre. An additional option has been proposed with 
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experienced interventionalists undertaking PPCI in peripheral catheter laboratories. PPCI is the preferred 
treatment option for STEMI when performed within guideline times, with the maximal acceptable PPCI-
related delay <120 min (<90 min  for young early presenters)7. Where PH-T is performed, this results in a 
reduction of 15-20% in early mortality, when compared with IH-T, and the combination of PH-T with early 
(but not immediate) coronary angiography and PCI further improves patients’ outcome. Appropriately 
educated and motivated healthcare professionals are central to overcoming existing barriers to provide 
optimal patient care.  Scientific societies have a critical role in promoting research and guideline 
implementation, whilst taking into account the the economic imbalances, and diversity of healthcare systems 
amongst the European countries.5 Finally, adequate involvement of political and administrative bodies is 
mandatory.    
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Legend Figure 1 
Components of total delay to reperfusion in patients with STEMI. Redrawn after Fox & Huber.2 
FMC = first medical contact;  D2N (door-to-needle) =  interval between FMC and the start of fibrinolytic 
drug administration; D2B (door-to-balloon) =  interval between FMC and infarct-related artery (IRA) 
reopening (by guidewire placement, thrombus aspiration or balloon inflation, whichever comes first). For the 
other abbreviations, see text. 
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Table 1 - European Registries on pre-hospital STEMI care 
name country primary end-point results 
Royal Victoria 
Hospital 
United 
Kingdom 
PHT vs IHT  call to thrombolysis time 
 mortality 
USIC France PHT + PCI    mortality with PHT + PCI, in comparison 
with IHT, PPCI and non-reperfused pts 
FAST-MI France PHT+PCI vs PPCI comparable results 
RISK-HIA Sweden PHT vs IHT vs PPCI PPCI had the lowest mortality, followed by 
PHT and then by IHT 
MINAP United 
Kingdom 
Reinfarction following PHT The lag phase between UFH bolus and start 
of infusion is critical for outcome 
Vienna Austria Implementation of a STEMI 
city system of care (cath-lab 
rotation, PHT) 
vs. pre-implementation period: 
 % reperfused pts 
 mortality 
Bologna Italy Implementation of a STEMI 
provincial tiered system of 
care (PHT+PCI, PPCI) 
vs. pre-implementation period: 
 % PPCI,  % TT,  % reperfused pts 
 in-hospital and long-term mortality 
NORDISTEMI * Norway TT (57% PHT) + immediate 
routine vs later selective 
transfer 
 MACE 
* randomized clinical trial;  pts = patients;   = increase;   = decrease; for other abbreviations, see text 
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Table 2 – Pre-hospital adjuvant antithrombotic therapies 
drug dose indication 
aspirin 150 mg p.o. * 
250-500 mg e.v.** 
all STEMI pts 
clopidogrel 300 mg p.o. 
600 mg p.o. # 
75 mg p.o. 
PPCI and TT in pts < 75 yrs 
advisable in PPCI  
TT in pts > 75 yrs 
UFH 100 U/kg iv bolus 
60 U/kg (max 4000 U) iv bolus + 12 U/kg/h (max 
1000 U/h) iv infusion 
PPCI  
TT and in non reperfusion Rx pts  
enoxaparin 30 mg iv bolus + 1 mg/kg/12 h (max 1000 U/12 h) 
no bolus + 0.75 mg/kg/12 h (max 75 mg/12 h) 
doses every 24 hrs 
TT and in non reperfusion Rx pts 
TT pts > 75 yrs   
pts with CrCl < 30 ml/min 
fondaparinux § 2.5 mg sc bolus + 2.5 mg sc qd TT and in non reperfusion Rx pts  
* non-enteric coated formulation, chewed;   ** when oral ingestion is not possible; # off-label dosage;            
§ contraindicated in pts with CrCl < 20 ml/min; pts = patients;  Rx = therapy; CrCl= creatinine clearance; 
for the other abbreviations, see text. 
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ACS    Acute coronary syndromes 
AED    automated external defibrillator 
AMI    acute myocardial infarction 
CS    cardiogenic shock 
D2B    door-to-balloon time 
D2N    door-to-needle time 
EM    emergency medicine 
EMS    emergency medical service 
IACC    intensive acute cardiac care 
ICCU    intensive cardiac care unit 
IH-T    in-hospital thrombolysis  
MACE    major adverse cardiac events 
NSTEMI   non-ST elevation myocardial infarction 
PDT    patient's decision time  
PH-ECG   pre-hospital electrocardiogram 
PH-T    pre-hospital thrombolysis 
PCI    percutaneous coronary intervention 
PPCI    primary percutaneous coronary intervention 
RCTs    randomised clinical trials 
ROSC    return of spontaneous circulation 
SRC    STEMI receiving centre 
STEMI    ST elevation myocardial infarction 
TT    thrombolytic therapy. 
